Hepatology Response to Reviewers: Liver Evidence Revision Guide

For every headline conclusion, connect these layers:

An intervention can be biologically active in liver tissue without modeling the human etiology. A prognostic marker can be associated with outcome without being treatment actionable. Keep those distinctions visible.

Hepatology manuscripts often pool heterogeneous liver disease to increase sample size. Before defending that choice, inspect effect modification across:

1. metabolic, alcohol-related, viral, autoimmune, cholestatic, genetic, or drug-induced etiology;
2. compensated versus decompensated disease;
3. fibrosis or cirrhosis stage;
4. active treatment and treatment response;
5. transplant eligibility and timing;
6. cancer status where relevant;
7. sex, age, ancestry, metabolic state, and center;
8. biopsy, imaging, or laboratory ascertainment.

Do not create underpowered subgroup certainty. Report intervals, state exploratory status, and narrow the main population when pooling is not defensible.

A higher AUC is not automatically a clinically useful biomarker. State the target population, decision point, comparator, threshold consequence, and validation boundary.

Differentiate reviewer comments and author responses with bold labels, boxes, or indentation. Do not rely on color. Keep handling-editor priorities, reviewer text, quoted revised sentences, and author interpretation visually separate.

In the marked manuscript requested by your portal, make changes to phenotype definitions, denominators, time origins, competing events, histology criteria, and conclusion scope conspicuous. Recheck page and line locations after final file conversion.

Concede model and population boundaries directly. Push back by explaining why a requested liver model or analysis would not answer the uncertainty raised.

In our pre-submission review work with Hepatology manuscripts, we audit the disease definitions, cell compartments, models, histology and imaging, biomarkers, endpoints, competing events, statistics, figures, reporting, abstract, and clinical interpretation. We map every reviewer request to the liver construct it tests and trace the revised population boundary into the conclusion. These are qualitative Manusights patterns, not Hepatology acceptance statistics or confidential review access.

Pattern 1: hepatic location becomes liver-specific mechanism

A signal is measured in liver tissue or a hepatocyte-like line and described as a liver-disease mechanism. In Hepatology revisions, we inspect cell source, perturbation, rescue, temporal order, tissue composition, and whether the model reproduces the relevant etiology. Location alone does not establish mechanism. We see this gap when bulk-tissue expression is interpreted as hepatocyte regulation despite changing immune or stromal composition.

Pattern 2: one injury model stands in for every etiology

The response adds more animals or time points in the same dietary, toxic, surgical, or genetic model. For Hepatology manuscripts, we ask which disease feature the model captures and which it misses. Cross-model evidence can support robustness; otherwise the paper should name the specific injury process rather than general liver disease. We audit etiology, fibrosis stage, metabolic state, and treatment context before treating replication as transport.

Pattern 3: phenotype precision is lower than model precision

The statistical model uses many covariates, but fibrosis, decompensation, etiology, treatment, or histology quality is loosely defined. We repair the phenotype table and time origin before adding predictors. Sophisticated estimation cannot correct an ambiguous outcome.

Pattern 4: transplant and death are treated as ordinary censoring

For progression or decompensation outcomes, these events can be related to severity and care decisions. We make the estimand explicit and test competing-risk or multi-state formulations. The response should say what clinical probability is being estimated.

The distinctive Hepatology information gain is liver-context alignment: compartment, etiology, model, phenotype, analysis, and clinical sentence must refer to the same disease process.

Check the Hepatology response and revised liver evidence together.

One reviewer may ask for deeper mechanism while another requests stronger clinical generalization. Explain the evidence layers to the editor. A cell-specific perturbation can support mechanism in a model; an external cohort can support transport of an association. Do not let either result claim what only the other could establish.

If a reviewer requests terminology or thresholds that conflict with current disease definitions, cite the current authoritative guidance and explain the mapping. Update the manuscript consistently rather than changing one reply.

Revision is not acceptance. Most serious rejection-on-revision risks include a non-liver-specific mechanism, a model that misses the stated etiology, imprecise phenotype or histology, confounding by treatment or severity, ignored competing events, internally validated biomarkers sold as clinical tools, and conclusions broader than disease stage and setting.

Most dangerous is a polished response that adds analyses while leaving the central liver-disease construct ambiguous.

We reviewed AASLD's current journal overview, Hepatology's public journal page, AASLD's publication-success materials covering reviewer feedback, and the current live submission context available through the journal pages. We then applied the liver-evidence alignment audit above. Public sources establish scope and educational context; the model and phenotype framework is Manusights analysis.

Because the public pages do not expose one universal response-file specification for every current Hepatology decision, the actual decision letter and Editorial Manager task list remain authoritative. This page does not predict acceptance.

1. Confirm deadline, file labels, and revision path in the decision letter.
2. Put handling-editor priorities before reviewer sections.
3. Answer every comment and cite page, line, figure, table, cohort, assay, and analysis.
4. Match liver-mechanism language to cell-compartment evidence.
5. State what each disease model captures and misses.
6. Reconcile etiology, stage, treatment, phenotype, and time origin.
7. Verify histology, imaging, biomarker, and omics quality controls.
8. Handle clustering, missingness, confounding, transplant, and death explicitly.
9. Synchronize response, revised files, abstract, and conclusion.
10. Keep reviewer and author text visually distinct.

Do not judge this owner before 14 complete GSC days. On the 21-day checkpoint, verify that it owns Hepatology revision queries, then weigh indexation, visibility, clicks, position, and qualified review starts before keeping, revising, consolidating, or stopping. The 10,812 journal impressions support testing the hypothesis, not forecasting traffic.

AASLD sources establish journal scope and revision education. The liver-evidence alignment map is Manusights interpretation.